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Hypothesis: The role of acquired tubulointerstitial disease in the
pathogenesis of salt-dependent hypertension. We present a new hypoth-
esis to explain the development of salt-dependent hypertension in hu-
mans. We propose that hypertension has two phases: an early phase in
which elevations in blood pressure (BP) are mainly episodic and are
mediated by a hyperactive sympathetic nervous or renin-angiotensin
system, and a second phase in which BP is persistently elevated and that
is primarily mediated by an impaired ability of the kidney to excrete salt
(NaCI). We propose that the transition from the first phase to the second
occurs as a consequence of catecholamine-induced elevations in BP that
preferentially damage regions of the kidney (juxtamedullary and medul-
lary regions) that do not autoregulate well to changes in renal perfusion
pressure. The catecholamine response is associated with both an increase
in peritubular capillary pressure and a reduction in peritubular capillary
plasma flow, resulting in injury to the peritubular capillaries with ischemia
to the tubules and interstitium. The local injury triggers the release or
activation (angiotensin II, adenosine, renal sympathetic nerves) or inhibi-
tion (nitric oxide, prostaglandins, dopamine) of vasoactive mediators that
further augment ischemia and result in abnormal tubuloglomerular feed-
back and enhanced NaCI reabsorption. The peritubular capillary injury
with rarefaction simultaneously blunts the pressure natriuresis mecha-
nism. The combined effect of enhanced tubuloglomerular feedback and
impaired pressure natriuresis results in a defect in NaC1 excretion which,
on the exposure to salt, results in the development of persistent hyper-
tension. Evidence is provided to suggest that this may be the major
mechanism for the development of salt-dependent hypertension, and
particularly for the hypertension associated with blacks, aging and obesity.
Thus, essential hypertension may be a type of acquired tubulointerstitial
renal disease.
There is compelling evidence that essential hypertension results
from a defect in the kidney in which there is an impiaired ability to
excrete salt (NaC1) at normal blood pressure (BP) [1, 2]. This has
led many investigators to search for a genetic basis for the defect
in renal salt handling, such as alterations in structure or regulation
of sodium transport within the nephron [3], as has been recently
demonstrated in Liddle's syndrome [4].
While the concept that hypertension results ftom a genetic
defect in renal salt handling is appealing, there are a number of
clinical observations that are incongruent with such a mechanism.
Why, for example, do 30 to 40% of patients with hypertension
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show minimal changes in BP with salt restriction or salt loading
[5]? These patients, who typically are young (< 45 years) with
early or borderline hypertension [6], appear to excrete salt
normally [7, 8]. If the defect in NaC1 excretion is genetic, then why
does hypertension generally not develop until adulthood, and
what accounts for the increased prevalence with aging? Further-
more, why does salt sensitivity increase in both frequency and
magnitude over time [9]?
In this paper we propose a pathway for the development of
hypertension that could account for these observations. This
pathway incorporates and unifies many hypotheses of others, but
also introduces some new ideas that hopefully will stimulate
further interest and study. Specifically, we propose that hyperten-
sion consists of two phases (Fig. 1). The first phase is mediated by
a hyperactive sympathetic nervous system, or, less commonly, by
an activated renin-angiotensin system, similar to that proposed by
Julius [10, 11]. During this phase the elevations in BP are
primarily episodic and renal salt handling is normal. Although the
kidney has a remarkable ability to protect itself from changes in
renal perfusion pressure ('autoregulation'), both theoretical and
experimental evidence is provided to suggest that the autoregu-
latory response does not adequately protect the kidney from
repeated and exaggerated elevations in BP, particularly when
coupled with the vasoconstrictive action of norepinephrine and
angiotensin II to reduce renal blood flow. The functional and
structural adaptative responses to both inappropriate pressure
and relative ischemia combine to limit the ability of the kidney to
excrete salt. This acquired defect in excreting salt increases in
magnitude as tubulointerstitial injury evolves, resulting in salt-
sensitive, persistent hypertension.
THE INITIATION OF HYPERTENSION: A HYPERACTIVE
SYMPATHETIC NERVOUS SYSTEM AND/OR ACTIVATED
RENIN-ANGIOTENSIN SYSTEM
We would propose, as others have, that the development of
hypertension passes through stages in which the BP is initially
episodically elevated prior to becoming persistently elevated (Fig.
I).
In this regard, it is important to realize that BP is labile to a
degree in all individuals. Blood pressure not only follows a
circadian rhythm, with a fall in BP at night, but also has minute to
minute variations [12]. In 'normotensive' individuals systolic BP
may vary as much as 80 mm Hg per day, and almost everyone
exceeds 150 mm Hg systolic in a 24 hour period [13].
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However, the degree of BP variability varies greatly between
individuals, largely due to differences in activity of the sympathetic
nervous system (particularly as it relates to plasma norepineph-
rifle levels and baroreflex sensitivity) and to activation of the
renin-angiotensin system [14]. Some individuals have marked
hypertensive responses (>160 mm Hg systolic) with stress, iso-
tonic or isometric exercise, coitus, visits to the doctor's office
(so-called 'white coat' hypertension) and with certain drugs
(caffeine, alcohol, nicotine) [14]. Other persons in the same
situation have a substantially less pressor response.
There is evidence that individuals who have marked episodic
elevations in BP are at increased risk for developing persistent
hypertension. Over 50 years ago Levy et al reported in a study
involving over 22,000 subjects that the presence of episodic
elevations in BP was associated with a two- to fourfold increased
risk for developing persistent hypertension [151, Episodic hyper-
tension induced by exercise [16] or nocturnal sleep apnea [17] also
poses significant risks. Indeed, 'borderline' hypertension (defined
as BP that is either episodically elevated or persistently elevated
to a minimal degree) is the best overall predictor for the devel-
opment of persistent hypertension [181.
Why do some individuals have marked episodic elevations in
BP whereas others do not? Whereas in some situations it may
relate to external factors such as alcohol, in most patients the
episodic elevations in BP are due to a hyperactive sympathetic
nervous system induced by genetic, familial, or environmental
factors [10, 11]. Julius has provided convincing evidence that a
hyperactive sympathetic nervous system is involved in the early
phases of hypertension [10, 11]. Indeed, in these patients plasma
norepinephrine levels are frequently elevated [10, 19].
In some individuals with early or episodic hypertension there is
also evidence for activation of the renin-angiotensin system, as
noted by elevated plasma renin levels [20, 21]. This could be a
consequence of stimulation of the renin-secreting cells in the
juxtaglomerular apparatus by the renal sympathetic nerves [22] in
response to the general activation of the sympathetic nervous
system. Patients inheriting certain angiotensinogen genotypes
associated with elevated blood levels of angiotensinogen are also
at risk for increased activation of the renin-angiotensin system and
the development of hypertension [23].
We suggest that the norepinephrine or angiotensin II mediated
elevations in BP, particularly if characterized by inappropriate
frequency or severity, may underlie the transition from episodic,
salt-resistant hypertension to persistent, salt-sensitive hyperten-
sion. However, in order to understand how this could devleop, we
must first discuss the normal mechanism by which the kidney
protects itself from acute changes in perfusion pressure, and the
mechanisms by which the kidney alters its sodium handling in the
setting of changing renal hemodynamics.
RENAL AUTOREGULATION AND SALT HANDLING IN
RESPONSE TO CHANGING RENAL HEMODYNAMICS
The kidney has a well developed protective response to cope
with alterations in systemic pressure, primarily as a way to
maintain renal blood flow and glomerular filtration rate (GFR)
[24]. Thus, acute elevations in systemic BP are followed by an
autoregulatosy response in which the preglomerular vessels (af-
ferent arterioles and interlobular artery [25]) vasoconstrict,
thereby preventing transmission of the elevated pressures to the
glomeruli and postglomerular capillary bed. This autoregulatory
response is mediated by two mechanisms: a myogenic reflex in
which the smooth muscle cells in the arteriolar walls undergo
reflex contraction following acute distention (mediated in sec-
onds) and a second mechanism in which increased NaCl delivery
to the distal tubule triggers a vasoconstrictive response of the
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Fig. 1. Schema for pathogenesis of salt
dependent hypertension. The hypothesis
proposes that early hypertension is episodic and
is mediated by a hyperactive sympathetic
nervous system or activated renin angiotensin
system. The acute norepinephrine or
angiotensin II mediated elevations in BP are
transmitted to the peritubular capillaries of the
kidney in association with a reduction in blood
flow secondary to the vasoconstrictive
properties of these substances. Capillary
damage and tubulointerstitial injury with
fibrosis results. The local ischemia stimulates
[adenosine, local angiotensin II, renal nerve
sympathetic activity (RSNA)1 or inhibits [nitric
oxide (NO), prostaglandins, dopamine]
vasoactive mediators, resulting in NaCl
reabsorption due to enhanced tubuloglomerular
feedback. The capillary damage and increase in
renal vascular resistance also blunts the
pressure natriuresis mechanism. The
consequence of both enhanced
tubuloglomerular feedback and impaired
pressure natriuresis is an acquired functional
defect in NaCI excretion. This results in a
resetting of the pressure-natriuresis curve to a
higher pressure in order to restore sodium
balance back to normal.
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afferent arteriole [tubuloglomerular (TG) feedback; mediated in
20 to 30 secondsl [241. As a consequence, cortical peritubular
capillary pressures change minimally (< 5 mm Hg) over a
physiological range of perfusion pressures, approximately 60 to
150 mm Hg [24, 261.
Central to renal autoregulation is TG feedback, which influ-
ences not only afferent arteriolar tone but also affects NaCl
excretion. As mentioned above, TG feedback occurs when there is
an increased NaC1 delivery to the macula densa, a region of the
distal tubule that is adjacent to the afferent arteriole. Specialized
cells in the macula densa respond to the excess NaCl by increasing
chloride transport via a chloride transporter which is an ATPase.
Adenosine is generated as an end product of the metabolism of
ATP and diffuses to the adjacent arteriole which express adeno-
sine (A1) receptors, and mediates avasoconstrictive response [27].
The afferent arteriolar vasoconstriction will reduce glomerular
pressure and diminish filtration of NaCl into the tubular lumen.
Although TG feedback is induced by NaCI delivery to the
macula densa, the magnitude of the vasoconstrictive response
('TG feedback sensitivity') can be modulated by a variety of
factors. For example, angiotensin II enhances the TG feedback
response [28], whereas nitric oxide and dopamine dampen TG
feedback sensitivity [29, 30]. TG feedback is also modulated by
plasma volume, with an elevation in extracellular volume reducing
TG feedback sensitivity, perhaps due to down regulation of the
local renin-angiotensin system [31].
In the setting of acute elevations in BP, the activation of the TG
feedback autoregulatory response might therefore be expected to
not only protect the glomerulus from the elevated pressures, but
to reduce NaC1 loss due to the effect of TG feedback to diminish
filtration. The degree of this TG feedback response, however, will
depend to some extent on the volume status and on local
concentrations of angiotensin II, adenosine and nitric oxide.
Furthermore, in situations in which local levels of angiotensin II
and adenosine are elevated, or in which nitric oxide levels are low,
NaC1 retention will be enhanced not only due to increase TG
feedback sensitivity, but due to direct effects of these substances
to enhance NaC1 reabsorption in the tubules [32—34].
Whereas TG feedback is a normal homeostatic mechanism that
promotes NaCl retention, it is counterbalanced by a mechanism
termed 'pressure-natriuresis' in which acute elevations in BP
result in increased NaCI excretion [351. The mechanism for this
pressure natriuresis does not appear to be due to increased
filtration, because, as discussed above, the renal autoregulatory
response acts to maintain the GFR. However, there is evidence
that the autoregulatory response is less efficient in the nephrons in
the deeper (juxtamedullary) regions of the kidney [36—38]. In-
deed, acute elevations in BP have been demonstrated to raise
peritubular capillary and interstitial pressures in this region
[36—38]. The increased interstitial pressure, in turn, would be
transmitted throughout the renal parenchyma, including to the
cortex [39]. The consequences of the elevated interstitial hydro-
static pressure is to passively retard NaC1 reabsorption, by allow-
ing a paracellular hackleak of sodium through the tight junctional
complexes of the proximal tubule [40]. Sodium excretion is also
facilitated in the descending limb of Henle of the deeper
nephrons, and, to a lesser extent in the medullary collecting duct
[41, 42].
Thus, NaCI reabsorption or excretion is largely balanced by two
opposing forces that are activated during acute elevations in BP:
a TO feedback mechanism which acts to enhance NaCI retention,
and a pressure natriuresis mechanism that acts to enhance NaCI
excretion. Perturbation of this delicate balance may underlie the
pathogenesis of essential hypertension.
RENAL RESPONSE TO EPISODIC ELEVATIONS OF
BLOOD PRESSURE INDUCED BY ACTIVATION OF THE
SYMPATHETIC NERVOUS AND RENIN-ANGIOTENSIN
SYSTEMS
To return to the hypothesis, we have proposed that acute
elevations in BP induced by a hyperactive sympathetic nervous
system or renin-angiotensin sytem adversely affects the kidney
(Fig. 1), despite the well equipped autoregulatory response dis-
cussed above. How and why would this happen?
We suggest that renal autoregulation may not be completely
protective. First, autoregulation is not instantaneous, so acute
changes in pressure may be transiently transmitted to the glomer-
ular and postglomerular capillaries. Second, most studies exam-
ining autoregulation have examined perfusion pressures ranging
from 80 to 150 mm Hg [24, 26], and have not excluded the
possibility that there may be a threshold pressure (> 160 mm Hg)
above which autoregulation may be incomplete. Indeed, in rats
with markedly elevated BP, both peritubular capillary and inter-
stitial pressures were elevated when measured by micropuncture
[43]. Furthermore, most approaches that have evaluated renal
autoregulation have manipulated perfusion pressure by mechan-
ical means, as opposed to using vasoactive agents that may
modulate not only blood flow within the main renal artery but also
may affect intrarenal hemodynamics. Thus, it is interesting that
norepinephrine acutely raises peritubular capillary pressure when
infused into rats [44]. Angiotensin II at subpressor doses also
causes a mild elevation in peritubular capillary pressure [44]; this
effect on the peritubular capillary is likely more exaggerated at
pressor doses, as evidenced by the marked pressure natriuresis
that results [45]. Finally, there is evidence that the renal autoreg-
ulatoiy response may be less efficient in the deeper (juxtamedul-
lary and medullary) regions of the kidney [36—38], although this
remains controversial [46]. Acute increases in renal perfusion
pressure have been shown to result in increased peritubular
capillary and interstitial pressures in this region [36—38].
Therefore, transient elevations in BP induced by a hyperactive
sympathetic nervous system or by elevated angiotensin II levels
would be expected to result in some increased transmission of
pressure to the peritubular capillaries (preferentially in the jux-
tamedullary region) and to the interstitium. Whereas this acute
increase in pressure might be expected to result in a concomitant
increase in local blood flow were it mediated by vascular volume
expansion alone, this is not true when the increased pressure is
mediated by angiotensin II or norepinephrine. The marked
vasoconstrictive action of these agents on the efferent and preglo-
merular vessels results in a 30 to 40% decrease in blood flow to
the peritubular capillaries of the postglomerular circulation de-
spite the increase in peritubular capillary pressure [44]. Further-
more, there is evidence that angiotensin II can also decrease
blood flow to the juxtamedullaty and medullary regions by causing
vasoconstriction of the vasa rectae [47, 48]. Thus, in contrast to
experimental situations in which elevations in perfusion pressure,
induced by mechanical means or by acute volume expansion, are
associated with increased renal blood flow, elevated perfusion
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pressures attributable to vasoactive agents such as norepinephrine
or angiotensin II are associated with decrements in renal blood
flow. This has important implications for the long-term adaptation
of the kidney to elevated perfusion pressures, as will be detailed
below.
ACQUIRED RENAL INJURY RESULTS FROM
ALTERATIONS IN PERITUBULAR CAPILLARY PRESSURE
AND FLOW
Thus, acute elevations in BP induced by a hyperactive sympa-
thetic nervous system or activated renin-angiotensin system could
affect the renal parenchyma. Most of the elevation in pressure
would be dampened by vasoconstriction of the preglomerular
renal vasculature, presumably accounting for why these are the
sites of vessel hypertrophy and hyperplasia in the renal lesion
termed 'benign nephrosclerosis' [49, 50]. However, as discussed
above, episodic elevations in BP, particularly if greater that the
autoregulatoty threshold, could result in increased transmission of
pressure to the glomeruli and to the postglomerular vasculature,
particularly in the juxtamedullary region.
What are the consequences of increased pressure transmission
to the glomeruli and postglomerular vascular bed? Because of the
necessity of ultrafiltration, the glomerular capillaries are normally
subjected to mean pressures that are several-fold higher that
experienced by capillaries elsewhere in the body. The ability to
handle these pressures is largely due to the presence of the
smooth muscle-like mesangial cell and the podocyte, which pro-
vide tensile support to the capillary walls [51]. Nevertheless, it is
well established that prolonged elevations of glomerular pressure
can result in damage and sclerosis [52].
In contrast to the glomerular capillaries, the postglomerular
capillary network is even less adapted to protect itself from
increased pressure. The requirement that these capillaries receive
the solutes and water reabsorbed by the tubules necessitates a
simple vascular structure consisting of a delicate, fenestrated
endothelium and a porous basement membrane. These capillaries
are normally devoid of any smooth muscle cells or pericytes that
can provide protection for acute increases in pressure. As dis-
cussed below, it is injury to these capillaries that maybe critical for
the development of salt-dependent hypertension.
Effects of increased pressure on the peritubular capillaries
Several consequences could result from the acute elevations in
peritubular capillary pressure. As discussed above, the peritubular
capillary consists only of an endothelial cell and a basement
membrane. We have noted that short-term (3 to 7 days) elevations
in systemic BP induced by angiotensin II result in a remarkable
recruitment of smooth muscle-like 'myofibroblasts' that encircle
the peritubular capillaries, thus functioning as a new smooth
muscle cell layer (Fig. 2) [531. One wonders if this could represent
an adaptive response to increases in peritubular capillary pres-
sure, and that it may also function as a new site of renal vascular
resistance.
Pressure-induced endothelial injury could also affect the pro-
duction of vasoactive molecules. We have observed that aging
rats, which develop salt-dependent hypertension, have a marked
loss of endothelial nitric oxide synthase (eNOS) from their
peritubular capillaries [541. A loss in eNOS might be expected to
Fig. 2. A new site of renal vascular resistance in experimental hyperten-
sion. In normal kidneys, the vascular smooth muscle protein, a-smooth
muscle actin, is expressed only by smooth muscle cells in vasa rectae,
arterioles (arrows) and larger vessels (a). In contrast, in experimental
models of hypertension (in this case induced by angiotensin II infusion in
rats), a-smooth muscle actin is expressed by interstitial fibroblasts (ar-
rows) that encircle the peritubular capillaries, thus potentially functioning
as a smooth muscle cell layer with potential effects on renal vascular
resistance (b and c). (Adapted from [531) (immunoperoxidase x200, A
and B; x630, C)
result in a decrease in local nitric oxide (NO) and therefore could
potentiate local ischemia.
Finally, if injury is severe enough, peritubular capillaries could
be permanently damaged, leading to a reduction in peritubular
capillary number (rarefaction). This latter process has been
reported to occur in renal biopsies from patients with essential
hypertension [491.
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Fig. 3. Tubulointerstitial injury occurs in an experimental model of
hypertension. In rats with 2-kidney 1-clip Goldblatt hypertension, the
unclipped kidney that is exposed to elevated pressure develops tubuloin-
terstitial injury that preferentailly involves the juxtamedullary region
(arrows) [621 (Periodic acid Schiff stain, X100).
Effect of ischemia on the tubulointerstitium
The pressure-induced injury to the peritubular capillary endo-
thelium coupled with the local vasoconstriction induced by nor-
epinephrine and angiotensin II would also lead to ischemia to the
surrounding tubules and interstitium. The most vulnerable sites
for ischemic damage would be the metabolically active and
mitochondria-rich proximal tubules (S3 segment) and medullary
thick ascending limb of Henle, the latter of which is largely in the
juxtamedullary and outer medullary regions of the kidney [55]. A
decrease in blood flow in the peritubular capillaries would also
affect blood flow to the more distal vasa rectae that supply the
medulla, with the consequence that medullary ischemia would
also result.
STRUCTURAL CONSEQUENCE OF ALTERATIONS IN
PRESSURE AND FLOW: TUBULOINTERSTITIAL DISEASE
The consequence of peritubular damage with juxtamedullary
and medullaiy ischemia would be tubulointerstitial injury. In this
regard, we have reported that short-term (3 to 7 days) elevations
of BP induced by angiotensin II in the rat will result in tubuloin-
terstitial damage with tubular atrophy, macrophage infiltration,
and interstitial fibrosis, and that it preferentially affects the
juxtamedullary region [53]. Episodic hypertension in humans can
also cause target organ damage, including to the kidney where it
may manifest as microalbuminuria [56—611. Tubulointerstitial
disease also occurs in hypertension observed in other experimen-
tal models and in human hypertension (Fig. 3) [49, 50, 62, 63].
Particularly relevant has been recent studies in which we have
infused the catecholaniine, phenylephrine, into rats [64]. The
infusion of phenylephrine mimics the hyperactive sympathetic
nervous system state, and results in a marked increase in BP
lability with only a minor change (< 10 mm Hg) in overall mean
BP. Interestingly, those rats with the greatest BP variability
develop marked tubulointerstitial damage, especially to the jux-
tamedullaiy region, after eight weeks of infusion of the catechol-
amine.
FUNCTIONAL CONSEQUENCE OF JUXTAMEDULLARY
AND MEDULLARY ISCHEMIA: NACL RETENTION DUE TO
ABNORMALLY ENHANCED TUBULOGLOMERULAR
FEEDBACK AND IMPAIRED PRESSURE NATRIURESIS
How does tubulointerstitial damage and ischemia lead to
sodium retention? Certainly, if enough nephrons are damaged,
the functional reserve could be compromised and sodium excre-
tion could be impaired. However, essential hypertension usually
develops in the setting of normal renal function (GFR), so this is
an unlikely mechanism for causing sodium retention.
We propose that the local tubulointerstitial injury and ischemia
results in NaC1 retention by two mechanisms. First, we will
present evidence that ischemic tissue will result in the generation
or inhibition of vasoactive mediators that enhance or activate the
tubuloglomerular (TG) feedback mechanism and also have direct
effects to increase NaC1 reabsorption in the nephron. This could
result from the ability of the vasoactive mediators to increase the
TG feedback response to the same salt load (such as elevated
angiotensin II or low nitric oxide) or due to stimulation of afferent
arteriolar vasoconstriction independent of distal salt delivery
(such as adenosine). Teleologically, one can view this as an
attempt by the kidney to increase blood volume in the setting
where it senses local blood flow to be impaired. Second, we will
discuss how the tubulointersitial injury could impair the pressure
natriuresis mechanism. The combined effect of enhanced TG
feedback and impaired pressure natriuresis may account for the
defect in NaCI excretion observed in many cases of salt-dependent
hypertension.
Enhanced tubuloglomerular feedback as the mechanism for
NaCI retention in essential hypertension
Kurokawa has summarized evidence that TG feedback is
abnormally increased in experimental and human hypertension
[65]. We suggest that the mechanism for this enhanced response
is due to the generation or inhibition of several vasoactive
mediators in ischemic renal tissue that affect afferent arteriolar
tone and/or have direct effects on tubular handling of NaCI. These
include the following:
Nitric oxide. Nitric oxide is a potent vasodilator that has direct
effects on the tubular handling of sodium as well as on afferent
arteriolar tone [66]. In essential hypertension renal production of
nitric oxide is depressed [67]. The reduction in local nitric oxide
may be due to the expression of osteopontin by tubules at the sites
of injury. Osteopontin is expressed by renal tubules in both
experimental (Fig. 4) [68] and human (S. Thomas, A. Bohle and
R, Johnson, unpublished data) hypertension, and is known to
inhibit the inducible [69] and possibly constitutive [70] nitric oxide
synthases, and thereby would inhibit local nitric oxide production.
Osteopontin is also chemotactic and adhesive for monocytes, and
its expression is tightly correlated with interstitial fibrosis in both
animals and humans [68, 70—72]. Other factors in addition to
osteopontin may also reduce local nitric oxide levels. For example,
TGF-f3, which is increased in models of interstitial fibrosis [71, 73],
reduces nitric oxide levels by stimulating the enzyme, arginase
[741. TGF-f3 as well as ischemia stimulate renal tubules to produce
more osteopontin [75, 76], thus amplifying the injury.
There is evidence that low renal nitric oxide levels may have a
role in the pathogenesis of NaCl-dependent hypertension. Matt-
sen, Cowley and associates have shown that reducing renal
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blunts the effect of pressure-induced natruresis via stimulation of
the angiotensin type IT receptor (AT2) [87]. Angiotensin II may
also stimulate local TGF-p secretion [88], a major cytokine
implicated in interstitial fibrosis [731. Evidence that local angio-
tensin II generation occurs in the interstitial fibrosis accompany-
ing essential hypertension has not been provided, but there is
evidence that local angiotensin II is generated in the interstitial
fibrosis accompanying aging [891, a condition that is highly
associated with the development of NaCl-dependent hyperten-
sion.
Fig. 4. Osteopontin expression in an experimental model of hyperten-
sion. Osteopontin (dark stain, see arrow) is markedly expressed by tubules
in the juxtamedullasy region in the unclipped hypertensive kidney of rats
with 2-kidney 1-clip Goldblatt hypertension. (Indirect immunopreoxidase
stain, )<100).
medullary production of nitric oxide by the direct infusion of
either an L-arginine analog or antisense oligonucleotides will
cause a selective reduction in medullary blood flow, NaCl reten-
tion, and, chronically, the development of hypertension [77—79].
Furthermore, in two NaCl-dependent models of hypertension,
administration of L-arginine, which stimulates nitric oxide pro-
duction, attenuates or eliminates the hypertension [80, 81].
Adenosine. Another vasoactive mediator that is likely to be
involved in the enhanced TO feedback is adenosine. Adenosine
synthesis is markedly increased in ischemic kidney tissue [821. As
mentioned above, adenosine is an important mediator of TG
feedback [27], not only by mediating vasoconstriction of the
afferent arteriole due to preferential binding of the adenosine A1
receptor [83], but due to direct stimulation of sodium reabsorp-
tion in the proximal tubule and of chloride reabsorption in the
thick ascending limb and papillary collecting duct [32]. Both
structural and hemodynamic evidence suggests that afferent arte-
riolar vasoconstriction is a principal finding in essential hyperten-
sion [67, 84], and adenosine is an attractive mediator for this
response. Furthermore, blockade of the adenosine receptor (A1)
causes a natriuresis and lowers BP in individuals with essential
hypertension [85]. Adenosine A1 antagonists do not lower BP in
normotensive individuals [85], a predictable finding as adenosine
levels would not be expected to be high in the normal kidney.
Local renin-angiotensin system activation. Local activation of the
renin-angiotensin system could also be involved [84, 86]. Sealey
and colleagues have proposed that there may be regional heter-
ogeneity in the kidneys of hypertensive patients, in which renin is
suppressed in some nephrons but not others [84]. Local produc-
tion of angiotensin II would lead to more vasoconstriction and
could potentiate ischemia. It would also facilitate local sodium
reabsorption, as angiotensin II, like adenosine, directly promotes
sodium uptake by the proximal nephron [34]. Angiotensin II also
Renal sympathetic nerve activation. Tubulointerstitial disease
[90, 91] as well as low nitric oxide levels [92] will also activate the
renal sympathetic nerves, which act not only to stimulate renin
production but also have direct effects to enhance sodium reab-
sorption by the proximal tubule or by the thick ascending loop of
Henle [93, 94]. Activation of the renal sympathetic nerves could
also augment local vasoconstriction.
One might expect the ischemic kidney would also produce
vasodilatory substances to counter the vasoconstrictive effects of
local adenosine, angiotensin IT, or activation of the renal sympa-
thetics. However, the capacity of the ischemic kidney to release
these mediators is impaired in the setting of essential hyperten-
sion, possibly due to the ongoing injury to the tubules or the
capillary network supporting them. For example, dopamine, a
renal vasodilator and natriuretic substance produced by the renal
tubule [95], is depressed in essential hypertension [96, 97]. The
urinary excretion of vasodilatory prostaglandins are also de-
pressed in human hypertension [97]. POE2 is normally produced
by collecting ducts and renal interstitial cells in the outer medulla
[39]. These interstitial cells flank the vasa rectae as they descend
into the medulla, and concentrate towards the renal papillae [39].
However, with decreased blood flow (such as induced by isch-
emia), there may be a preferential diversion of blood flow to the
short loop capillary networks of the vasa rectae, thereby resulting
in a relative decrease in the amount of POE2 available [39].
Thus, the consequences of peritubular capillary damage with
local ischemia would be tubular injury with the stimulation
(adenosine, renin-angiotensin, sympathetic nerves) or inhibition
(nitric oxide, dopamine, prostaglandins) of vasoactive mediators
that would collectively act to cause local vasoconstriction and
enhance NaCl reabsorption. The net effect of sustained, inappro-
priately augmented TG feedback is to blunt the kidney's ability to
excrete salt in proportion to volume-driven increases in BP [98].
Further, because TG feedback also results in vasoconstriction of
the afferent arteriole, it may further augment the local ischemia.
Thus, a 'vicious circle' could develop in which local ischemia
induces expression of vasoactive mediators that exacerbate the
ischemia, with the consequence of injuring more tissue and
further enhancing NaCl reabsorption through the TG feedback
mechanism in a self-perpetuating and reinforcing manner (Fig. 1).
Impaired pressure natriuresis also results from
tubulointerstitial disease
The effect of abnormal TO feedback would be to enhance NaCl
retention, with the consequence that pressure-natriuresis would
be stimulated in order to achieve sodium balance. However, as
discussed above, pressure natriuresis is likely mediated by in-
creased hydrostatic pressures in the peritubular capillaries [40].
Normally there is a small pressure gradient across the peritubular
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capillary bed. However, in the setting in which there is an increase
in vascular resistance in the peritubular capillaries due to rarefac-
tion or to the generation of a smooth muscle cell layer, dampening
of the pressure across the peritubular capillary network would be
expected, and this should result in an impaired pressure natriure-
sis.
The consequence of both enhanced TG feedback and impaired
pressure natriuresis, both of which have been shown to occur in
experimental and human hypertension [35, 65], would be NaCI
retention. The rise in blood volume would initially increase
cardiac output and later systemic vascular resistance, both result-
ing in systemic hypertension. The rise in systemic vascular resis-
tance presumably has several causes, including: (1) stimulation of
central sympathetic nervous system activity from renal afferents
from the ischemic renal tissue [22, 90, 91]; (2) stimulation of
systemic vessel hypertrophy by the local renin-angiotensin system
and other mediators [99]; and (3) the stimulation [1001 or
inhibition [101] of circulating vasoactive substances that affect
peripheral vascular tone.
SUMMARY OF PATHWAY
We therefore propose that essential hypertension has two
phases. In the initial phase hypertension is primarily driven by a
hyperactive sympathetic nervous system, consistent with the hy-
pothesis put forth by Julius [10, 111. Although activation of the
renal sympathetic nerves in response to the generalized sympa-
thetic nervous overactivity might result in some NaCI retention
[221, the TG feedback and pressure natriuresis mechanisms are
intact, and as a result NaCl handling is normal. However, over
time the marked episodic elevations in BP induce peritubular
capillary damage. This structural injury, in concert with the
vasoconstrictive actions of angiotensin II and norepinephrine,
result in local ischemia with the generation of vasoactive media-
tors that upset the balance between TG feedback and pressure
natriuresis. The release of vasoconstrictor mediators (adenosine,
angiotensin II, sympathetic nerve activity) and inhibition of
vasodilator mediators (nitric oxide, dopamine, prostaglandins)
results in abnormal TG feedback. In addition, the increase in
renal vascular resistance in the peritubular capillary bed due to
rarefaction or to the generation of a smooth muscle cell layer may
cause the creation of a pressure gradient across the peritubular
capillary bed. This would dampen the pressure as it is transmitted
along the course of the peritubular capillaries, and would there-
fore result in an impairment of pressure natriuresis. The combi-
nation of these phenomena would lead to a NaCl retaining state,
and, in the setting in which the individual is exposed to salt, would
result in blood volume expansion with an increase in blood
pressure. As blood flow and renal perfusion pressure increases,
blood supply to the ischemic regions of the kidney is improved and
the TG feedback mechanism is turned off and pressure natriuresis
restored, allowing NaCl excretion to return to normal, at the
expense, however, of an elevated BP.
The importance of exogenous salt in 'unmasking' hypertension
in the setting of tubulointerstitial injury is exemplified in recent
studies in the angiotensin 11 infusion model [64]. In this model,
the infusion of angiotensin Il (200 ng/min) into rats results in
marked hypertension and modest tubulointerstitial injury but with
preservation of renal function. After stopping the infusion, rats
became normotensive. Subsequent exposure of the rats to high
(4%) but not low (0.1%) salt in their diet resulted in the
development of marked (BP > 170 mm Hg) hypertension after
several weeks. Rats on a high salt diet that had never been
exposed to angiotensin II remain normotensive.
Importantly, the pathway addresses some of the questions
raised in the introduction of this paper that are not readily
explained by a mechanism involving a genetic defect in renal salt
excretion. Thus, it explains why younger patients are more
frequently NaC1 resistant, with normal renal salt handling [7, 8]
and normal or low blood volumes [102—1051, whereas older
hypertensive patients are more likely to be NaCl-sensitive [6] and
to have elevated blood volumes [9, 1051. It also explains why NaC1
sensitivity increases in magnitude with time [9] and why salt-
dependent hypertension is more frequently associated with renal
injury such as microalbuminuria [106—1 081.
The hypothesis also explains why some hypertensive patients do
not have a normal fall in BP at night ('nocturnal dipping'). Thus,
it has been shown that patients with borderline or NaCI-resistant
hypertension usually have normal nocturnal dipping, consistent
with a reduction in sympathetic activity with sleep [1091. In
contrast, patients with NaCl-sensitivity [109] or with microalbu-
minuria [1101 usually show no nocturnal dipping. This may relate
to the presence of renal disease, for it is known that a loss of
nocturnal dipping is associated with the hypertension accompa-
nying primary renal disease [111, 112].
APPLICATION OF THE HYPOTHESIS TO HIGH RISK
POPULATIONS
The hypothesis also explains why certain high risk populations
may be susceptible to hypertension.
For example, blacks have enhanced BP responses to exercise
[113] or to norepinephrine [114] and are also postulated to have
a relative defect in their renal autoregulatory response to salt
loading [115]. They would therefore be predicted to have a higher
frequency of hypertension, increased target organ damage and
NaCI-sensitivity, all of which have been shown [1161.
Hypertension also increases progressively with aging. One
might expect this due to the cumulative effect of repeated injury to
the juxtamedullary and medullary region over time. Indeed, it is of
interest that the aging is associated with progressive tubulointer-
stitial fibrosis with osteopontin expression, reduction in eNOS,
local angiotensin II generation, decreased renal blood flow and
salt-dependent hypertension [54, 117, 118].
Obesity is also associated with an increased prevalence of
hypertension. Interestingly, obese individuals have been shown to
have an augmented sympathetic nervous system activity with
higher basal norepinephrine and plasma renin levels [119], with a
tendency to higher BP variability [120], glomerular hyperfiltration
[121] an increased prevalence of interstitial fibrosis and glomer-
ulosclerosis [122], an expanded extracellular volume [123], and
salt-dependent hypertension [123, 124].
Cyclosporine (C5A) therapy is also frequently complicated by
the development of hypertension. Cyclosporine A is a vasocon-
strictor that can directly inhibit nitric oxide production [125]. In
collaboration with W Bennett, we have shown that rats adminis-
tered CsA will develop interstitial fibrosis identical to that ob-
served in humans [70, 71]. The tuhulointerstitial injury preferen-
tially involves the juxtamedullary region [1261 and results in local
fibrosis with TGF-13 and osteopontin expression and a reduction
in eNOS [70]. Increasing nitric oxide synthesis by L-arginine
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administration is protective, whereas inhibition of nitric oxide
with L-NAME worsens the fibrosis and causes greater hyperten-
sion [70]. Furthermore, if the CsA administration is stopped after
the tubulointerstitial lesion develops, then placement of the
animals on a high salt diet results in the rapid development of
hypertension despite the presence of a normal GFR [641.
CsA therapy is also associated with interstitial fibrosis, os-
teopontin and TGF-/3 expression, and the development of salt-
dependent hypertension in humans [127—130].
HYPERTENSION MAY RESULT FROM ENTRY INTO THE
PATHWAY AT OTHER STAGES
We have proposed that episodic, labile hypertension injures the
renal tubulointerstitium as the initiating event in the pathogenesis
of essential hypertension (Fig. 1). However, elevated arterial
pressures could be transmitted to the interstitium through other
mechanisms. For example, vascular shunts that bypass the jux-
tamedullary glomeruli have been identified in renal biopsies and
would result in increased pressure transmission to the peritubular
capillaries. These juxtamedullary vascular shunts increase with
aging and are also increased in hypertensive subjects [131].
Hypertension could also occur if the interstitium is injured
through other mechanisms. Hypertension frequently accompanies
interstitial renal disease induced by hypercalcemia, chronic pye-
lonephritis, obstruction, heavy metals (lead), radiation, or associ-
ated with gout [1321.
Hypertension may also occur through mechanisms that directly
compromise renal medullary blood flow [36, 77—79]. Cyclosporine
A-mediated vasoconstriction likely involves this mechanism. An-
algesic abuse, in which the vasodilatory prostaglandins are chron-
ically inhibited, is also associated with a remarkable incidence
(> 85%) of hypertension [1331. The possibility that a genetic
reduction in medullary blood flow may account for some types of
hypertension can also not be dismissed. For example, the sponta-
neously hypertensive rat (SHR) has a selective reduction in renal
medullary blood flow before the rat becomes hypertensive [134].
Finally, mechanisms that directly result in decreased sodium
excretion could bypass proximal stages in the pathway. This would
include genetic diseases associated with impaired sodium excre-
tion or with enhanced sodium reabsorption due to abnormalities
or dysregulation of sodium transport (such as Liddle's syndrome,
glucocorticoid-remediable aldosteronism, and the syndrome of
apparent mineralocorticoid excess) [3, 4]. A genetic reduction in
nephron number has also been proposed by Mackenzie, Lawler
and Brenner [135] to cause hypertension. Following the principles
of the current hypothesis, one would not expect this to cause
hypertension until sufficient hyperfiltration resulted in significant
tubulointerstitial injury.
In conclusion, we have presented a potential pathway (Fig. 1)
for the development of salt-dependent hypertension in humans.
The hypothesis links early, episodic, salt-independent hyperten-
sion with the later development of a persistent salt-dependent
hypertension with the new concept that it is mediated by acquired
tubulointerstitial and peritubular capillary injury. A strength of
the hypothesis is that unites many prior hypotheses into one
pathway, including that of Julius on the role of the sympathetic
nervous system in early hypertension [10], of Cowley et al on the
role of medullary ischemia [36], of Sealey and Laragh on activa-
tion of the renin-angiotensin II system [841, of Guyton et al on
impaired pressure natriuresis [35], of Kurokawa on enhanced TG
feedback [65], and of Mackenzie, Lawler and Brenner on reduced
nephron number [135]. In addition, it potentially provides answers
to many questions not easily addressed by other individual
hypotheses. Future studies are needed to test aspects of this
hypothesis in both experimental animals and in humans.
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